What is RXST (RXST) stock price today?

RXST (RXST) is currently trading at $6.38, down 2.52% today.

What is RXST P/E ratio?

RXST's P/E ratio is -6.22. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is RXST return on equity (ROE)?

RXST's return on equity (ROE) is -17.35%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is RXST's market cap?

RXST has a market capitalization of $263.90M.

NASDAQ · Medical - Devices

RXST (RXST) Stock

$6.38 -2.52% NASDAQ: RXST Healthcare

Valuation

Metric	Value
Price	$6.38
Market Cap	$263.90M
P/E Ratio	-6.22
P/B Ratio	1.11
P/S Ratio	2.28
EPS (TTM)	$-0.95
52-Week High	$13.22
52-Week Low	$4.48
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-17.35%
ROA	-13.31%
ROCE	-20.24%
Gross Margin	-36.57%
Operating Margin	-35.82%
Net Margin	-36.80%
Debt/Equity	0.04
Current Ratio	11.04

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$23.0M	$49.0M	$89.0M	$140.0M	$134.0M
Operating Profit	$-53.0M	$-63.0M	$-50.0M	$-37.0M	$-48.0M
Net Profit	$-49.0M	$-67.0M	$-49.0M	$-27.0M	$-39.0M
EPS	$-1.78	$-2.41	$-1.41	$-0.71	$-0.95
Op Margin	-233.6%	-129.2%	-56.2%	-26.3%	-35.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$193.0M	$150.0M	$183.0M	$319.0M	$312.0M
Total Liabilities	$54.0M	$60.0M	$22.0M	$37.0M	$36.0M
Cash	$24.0M	$12.0M	$10.0M	$17.0M	$20.0M
Borrowings	$45.0M	$45.0M	$3.0M	$12.0M	$11.0M

Latest News

RxSight Names Aziz Mottiwala as CEO MT Newswires · Jul 15, 2026 RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer GlobeNewswire · Jul 15, 2026 RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook MarketBeat · Jul 11, 2026 Can Alcon Inc. (ALC) Stock Rebound as New Eye Care Products Approach Regulatory Milestones? Insider Monkey · Jul 8, 2026 Alcon, RxSight Launch Collaboration to Develop Adjustable Presbyopia-Correcting Lenses MT Newswires · Jul 6, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-45.0M	$-59.0M	$-42.0M	$-17.0M	$-16.0M
Investing Cash Flow	$-84.0M	$38.0M	$-27.0M	$-105.0M	$13.0M
Financing Cash Flow	$1.0M	$-1.0M	$-4.0M	$-6.0M	$-2.0M
Net Cash Flow	$11.0M	$-13.0M	$-2.0M	$7.0M	$3.0M
Free Cash Flow	$-47.0M	$-61.0M	$-46.0M	$-22.0M	$-19.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.19
EV / EBITDA	-6.66
FCF Yield	-9.33%
Quick Ratio	3.61
Interest Coverage	-3674.20
Return 1Y	-32.03%
Return 3Y	-82.48%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BFLY	$7.36	+0.96%	-25.43	$1.96B	0.00%
CERS	$2.59	+0.78%	-70.99	$521.95M	0.00%
DCTH	$16.48	+0.00%	1498.18	$568.92M	0.00%
DMAC	$6.75	+2.90%	-9.11	$363.71M	0.00%
KIDS	$22.41	-0.80%	-13.45	$575.60M	0.00%

About RXST

RXST is led by CEO Ronald Kurtz, employs 498 people, headquartered in US, publicly traded since 2021.

RXST stock trades at $6.38 with a market capitalization of $263.90M. The stock is valued at a price-to-earnings (P/E) ratio of -6.22, price-to-book of 1.11, price-to-sales of 2.28. Over the past 52 weeks the stock has ranged between $4.48 and $13.22, and currently trades 51.7% below its 52-week high.

On profitability, RXST generates a return on equity (ROE) of -17.35%, return on capital employed of -20.24%, an operating margin of -35.82%, a net profit margin of -36.80%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides